MedPath

Quercetin on thalassemia induced depressio

Phase 2
Conditions
beta thalassemia major.
Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia major
Registration Number
IRCT20091114002709N46
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
84
Inclusion Criteria

18 to 40 year old male and female beta thalassemia major patients
Inclination to cooperate and signing the written informed consent
A minimum of 2 years of blood transfusion history
blood specimen collection 20 days after the last blood transfusion
Regular and peculiar iron-chelating therapy with desferrioxamine
Vitamin C supplement intake with desferrioxamine

Exclusion Criteria

Uncontrollable and life threatening complication due to due to the supplement intake;; ; ; ; ; ;
A change in type or amount of the iron chelator
Pregnancy or lactation
Hepatitis infection and other metabolic or infectious diseases
Less than 80% compliance of supplement intake
Consumption of drugs that interfere with quercetin
Drinking more than 500 mg/day of beverages rich in flavonoids
Smoking or alcohol consumption

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression. Timepoint: before and after the intervention. Method of measurement: Beck's questionnaire.
Secondary Outcome Measures
NameTimeMethod
High-sensitivity C-reactive protein(hs-CRP). Timepoint: before and after the intervention. Method of measurement: using ELISA kit in Microgram/milliliter(micg/ml).;Tumor necrosis factor a(TNF-a). Timepoint: before and after the intervention. Method of measurement: using ELISA kit in Picrogram/milliliter(pg/ml).
© Copyright 2025. All Rights Reserved by MedPath